JUN 10, 2020 7:14 AM PDT

FDA Approves New Antibiotic for Hospital-Acquired Pneumonia

WRITTEN BY: Annie Lennon

The US Food and Drug Administration (FDA) has approved Recarbrio, an antibiotic drug created by pharmaceutical company Merck, to treat different varieties of bacterial pneumonia typically contracted in hospitals. 

Recarbrio is a mixture of antibiotic imipenem-cilastatin and the beta-lactamase inhibitor, relebactam, used to increase the efficiency of the active antibiotic. The drug has previously been approved to treat patients with complicated urinary tract infections and intra-abdominal infections who have limited or no other treatment options. 

Now, the agency has approved the drug for usage against hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by gram-negative microorganisms in people over 18 years old. 

Patients usually contract HABP and VABP types of pneumonia in hospital settings. Symptoms include fever, chills, cough, chest pain, and an increased need for oxygen. 

To assess the safety of the drug for HABP/VABP, researchers conducted a randomized, controlled clinical trial involving 535 with either condition. While 266 patients were treated with Recarbrio intravenously, the remaining 269 were treated with piperacillin-tazobactam, another drug with antibacterial properties. 

In the end, the researchers found that while 21.3% of those on piperacillin-tazobactam died before Day 28 of the study, the same was true for only 15.9% of patients on Recarbrio. Meanwhile, the clinical response at early follow-up was 61% for those on Recarbrio, whereas just 55.8% for the control drug. 

Negative side effects for Recarbrio included anemia, diarrhea, hypokalemia (low potassium levels), and hyponatremia (low sodium levels). Before qualifying for treatment with Recarbrio, patients are urged to share information on previous hypersensitivity reactions to allergens that could hamper treatment. 

The FDA also notes that the drug should not be used in patients prone to seizures and other nervous system disorders. As with almost all antibacterial drugs, Recarbrio leads to Clostridioides difficile-associated diarrhea and may range from mild diarrhea to fatal colitis. 


Sources: FDA, Yahoo News, Drug Topics

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
JUN 09, 2020
Drug Discovery & Development
Arthritis Drug May Reduce COVID-19 Deaths by 45%
JUN 09, 2020
Arthritis Drug May Reduce COVID-19 Deaths by 45%
Researchers from the University of Michigan have found that tocilizumab, an immunosuppressive drug used to treat arthrit ...
JUN 13, 2020
Neuroscience
High Doses of Ketamine Can Switch Off the Brain
JUN 13, 2020
High Doses of Ketamine Can Switch Off the Brain
Researchers from the University of Cambridge, England, have found that high doses of ketamine temporarily switch off the ...
JUN 24, 2020
Drug Discovery & Development
Gilead to Test Inhalable Remdesivir Against COVID-19
JUN 24, 2020
Gilead to Test Inhalable Remdesivir Against COVID-19
Gilead has announced that it will soon start trials for an inhalable form of Remdesivir, the first drug to receive Emerg ...
JUL 07, 2020
Immunology
Existing drugs can prevent SARS-CoV-2 from hijacking cells
JUL 07, 2020
Existing drugs can prevent SARS-CoV-2 from hijacking cells
An international team of researchers has analysed how SARS-CoV-2, the virus that causes COVID-19, hijacks the proteins i ...
JUL 19, 2020
Drug Discovery & Development
Nanodrug for Treating Invasive Breast Cancer
JUL 19, 2020
Nanodrug for Treating Invasive Breast Cancer
Scientists at the University of Arkansas created a nano-drug that may eradicate triple-negative breast cancer cells. Fin ...
JUL 25, 2020
Drug Discovery & Development
New Method for Targeting The Herpes Virus
JUL 25, 2020
New Method for Targeting The Herpes Virus
A new way for treating the human herpes viruses was recently discovered by researchers at Lund University in Sweden. The ...
Loading Comments...